Jacobs Levy Equity Management’s Unity Biotechnology UBX Stock Holding History

Jacobs Levy Equity Management’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-54,152	Closed	-$1.63M	–	1076
2021 Q3	$1.63M	Sell	54,152 -21,840	-29%	-$771K	0.01%	654
2021 Q2	$3.53M	Buy	75,992 +18,448	+32%	+$888K	0.02%	498
2021 Q1	$3.45M	Buy	57,544 +18,048	+46%	+$1.23M	0.03%	501
2020 Q4	$2.07M	Buy	39,496 +28,008	+244%	+$1.35M	0.02%	577
2020 Q3	$397K	Sell	11,488 -13,537	-54%	-$857K	﹤0.01%	844
2020 Q2	$2.17M	Sell	25,025 -6,480	-21%	-$481K	0.02%	519
2020 Q1	$1.83M	Sell	31,505 -2,245	-7%	-$141K	0.02%	499
2019 Q4	$2.43M	Buy	+33,750	New	+$2.38M	0.02%	511
2019 Q2	–	Sell	-3,450	Closed	-$280K	–	1027
2019 Q1	$280K	Buy	+3,450	New	+$391K	﹤0.01%	848

Other funds holding UBX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Jacobs Levy Equity Management's UBX Position: Q4 2021 in Review

Jacobs Levy Equity Management sold out of Unity Biotechnology (UBX) in Q4 2021, closing a stake of 54,152 shares — an estimated $1.63M sold.

Jacobs Levy Equity Management first reported a position in UBX in Q1 2019 and held it in 9 quarters. The position peaked at $3.53M in Q2 2021. 71 funds tracked by Wall St. Rank hold UBX as of Q4 2021.

Jacobs Levy Equity Management reported no remaining Unity Biotechnology position as of Q4 2021 after selling out during the quarter.
Jacobs Levy Equity Management sold 54,152 Unity Biotechnology shares in Q4 2021, an estimated $1.63M.
Jacobs Levy Equity Management first reported a position in Unity Biotechnology in Q1 2019 and held it in 9 quarters.
Jacobs Levy Equity Management's Unity Biotechnology position peaked at $3.53M in Q2 2021.
71 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2021, filed 14 Feb 2022.